Tonix Pharmaceuticals Holding (TNXP) Fair Value & Analysis
Healthcare · US · Market cap $191M
Tonix Pharmaceuticals Holding
TNXP · US
Fair value as of: Jul 21, 2026
From 3 valuation models · updated today
Share price −8.6% over the past month.
Price vs Fair Value (12 months)
12‑month range $10.65 – $61.57 · fair‑value band $2.16 – $4.12 · the $10.98 price screens above the $3.35 fair value. As of Jul 21, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Tonix Pharmaceuticals Holding (TNXP) currently trades at $10.98, while our model-based Fair Value estimate is $3.35, implying the stock looks roughly 69.5% overvalued today. We read business quality at 18/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).
Trailing-twelve-month revenue stands at $17.6M. Revenue grew 183.2% year over year. It earns a return on equity of -72.3%. The balance sheet holds a net cash position of $206M. Fundamentals as of Jul 21, 2026
Our scenario range runs from $2.16 (bear case) to $4.12 (bull case); at $10.98, the current price sits above that range. For context, the median of 10 Healthcare peers we cover trades at -27% fair-value upside, at -70%, TNXP screens richer than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 21, 2026. TTM = trailing twelve months.
About the company
Tonix Pharmaceuticals Holding Corp., a fully integrated biopharmaceutical company, develops and commercializes therapies for central nervous system (CNS) disorders, immunology and immuno-oncology, infectious diseases, and rare diseases in the United States. The company offers TONMYA, a cyclobenzaprine HCl sublingual tablet for the treatment of fibromyalgia. It also markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. In addition, the company develops TNX-102 SL, a cyclobenzaprine HCl sublingual tablet for the treatment of major depressive disorder and acute stress reaction/acute stress disorder; TNX-1300, a double-mutant cocaine esterase for the treatment of cocaine intoxication; TNX-1500, an Fc-modified humanized monoclonal antibody to prevent kidney transplant rejection, as well as to treat autoimmune conditions; TNX-4800, a humanized monoclonal antibody for the seasonal prevention of Lyme disease; and TNX-2900, an intranasal …
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Tonix Pharmaceuticals Holding reported revenue of $13.1M in FY2025 versus $0 in FY2021. Reported net income was −$124M in FY2025.
Is TNXP fairly valued? → Check now
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jul 21, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX | 7,746 MXN | 5,617 MXN | -27% |
| Regeneron Pharmaceuticals, Inc REGN34 | R$52.30 | R$9.67 | -82% |
| UCB SA UCB | €247.60 | €180.06 | -27% |
| argenx SE ARGNF | $900.00 | $382.64 | -57% |
| Samsung Biologics Co 207940 | 1,000,000 KRW | 1,091,384 KRW | +9% |
| CSL Limited CSL | A$116.32 | A$126.60 | +9% |
| Celltrion, Inc 068270 | 171,400 KRW | 74,280 KRW | -57% |
| BioNTech SE B1NT34 | R$28.41 | R$23.67 | -17% |
| WuXi Biologics (Cayman) Inc 2269 | HK$37.56 | HK$26.11 | -30% |
| Innovent Biologics, Inc 1801 | HK$85.35 | HK$21.13 | -75% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Tonix Pharmaceuticals Holding (TNXP) undervalued?
What is the fair value of TNXP?
What is the quality score of TNXP?
What is the revenue of Tonix Pharmaceuticals Holding (TNXP)?
What is the net profit margin of TNXP?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Unlock the full Tonix Pharmaceuticals Holding analysis, and try Pro free
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.